ESTRO 2024 - Abstract Book

S2203

Clinical - Upper GI

ESTRO 2024

Figure 1. LRFS and OS in the three groups of Oligometastatic Disease.

Conclusion:

SABR for liver metastasis in OMD is an effective and well-tolerated in all settings of pts. In our cohort no statistical difference was observed in the 3 main OMD groups. Probably larger cohorts and longer follow-up are needed to observe a difference in groups of patients who theoretically have different prognostics.

Keywords: Liver, SBRT, oligometastasis

1749

Poster Discussion

Dosimetry and survival in unresectable primary HCC patients undergoing resin 90 Y SIRT

Miriam Santoro 1 , Giuseppe Della Gala 1 , Giulia Paolani 1 , Elisa Lodi Rizzini 2 , Arber Golemi 3 , Alberta Cappelli 4 , Cristina Mosconi 4 , Letizia Calderoni 3 , Elena Tabacchi 3 , Sandra Rea 5 , Sara Ungania 6 , Rosa Sciuto 5 , Lidia Strigari 1 1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical Physics, Bologna, Italy. 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Radiation Oncology, Bologna, Italy. 3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Nuclear Medicine, Bologna, Italy. 4 IRCCS Azienda Ospedaliero-Universitaria di Bologna,